

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lustig et al.

Group Art Unit: 1646

Serial No. 09/163,713

Examiner: Michael D. Pak

Filed: September 30, 1998

Attorney Docket No. T97-012-1

For: Nuclear Hormone Receptor Drug Screens

## CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted by fax to the Comm for Patents at (703) 308-4242 on November 14, 2000

Signed

Richard Osman

AMENDMENT

FAX RECEIVED

NOV 15 2000

GROUP 1600  
OFFICIALThe Commissioner for Patents  
Washington, DC 20231

Dear Commissioner:

In view of our amendments made in copending Serial No.08/975,614, please enter the following amendments in this application:

## IN THE CLAIMS

Please cancel all pending claims and add new claims 32-61 as follows:

32. (New) An in vitro assay method for modulators of a nuclear hormone receptor binding function, comprising steps:

forming an in vitro mixture comprising a first nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the first receptor, wherein the sensor consists of a peptide comprising the sequence  $L_1X_1X_2L_2L_3$  (SEQ ID NO:18) covalently coupled to a detectable label, wherein  $L_1$ - $L_3$  are independently selected from hydrophobic amino acids and  $X_1$ - $X_2$  are independently selected from any amino acid and wherein the peptide provides direct, in vitro ligand-dependent binding to the first receptor and is 24 or fewer residues in length;

measuring an agent-biased binding of the sensor to the first receptor by detecting the sensor of immobilized first receptor-sensor complexes;